University of California, San Francisco Logo

University of California, San Francisco | About UCSF | Search UCSF | UCSF Medical Center

Home > Grand Rounds > HIV Prevention
Treatment Guidelines and the Interface with Prevention
greyline
transparent gif
transparent gif
Paul Volberding
Back to CME Grand Rounds
Description
Presenter: Paul A. Volberding, MD
Video ClipWatch the Presentation Flash Icon View in FlashReal Icon View in Real
SlidesView Slides Without Audio
Description

Dr. Volberding discusses the recent shifts in U.S. HIV treatment guidelines, especially regarding early initiation of ART, and reviews data on efficacy of ARVs in preventing sexual transmission of HIV. He discusses both ART for HIV-infected persons and preexposure prophylaxis for uninfected persons.

Presenter: Paul A. Volberding, MD

Dr. Volberding is a professor and vice chair of the Department of Medicine and director of the Center for AIDS Research at the University of California, San Francisco (UCSF), and Chief of Medical Services at the San Francisco Veterans Affairs Medical Center. Dr. Volberding’s professional activities centered for more than 20 years at SFGH, where he established a model program of AIDS patient care, research, and professional education. His research career began with investigations of HIV-related malignancies, especially Kaposi's sarcoma. His primary research focus, however, shifted to clinical trials of antiretroviral drugs. He has been instrumental in testing many compounds, but is best known for groundbreaking trials establishing standards of care for the use of zidovudine in asymptomatic HIV infection and for continuous service on the two major guidelines panels for antiretroviral therapy.